Chao Guo Selected Research

3,4-dihydroxyphenyllactic acid

12/2017	Synergistic neuroprotective effects of Danshensu and hydroxysafflor yellow A on cerebral ischemia-reperfusion injury in rats.
11/2017	Danshensu accelerates angiogenesis after myocardial infarction in rats and promotes the functions of endothelial progenitor cells through SDF-1α/CXCR4 axis.
2/2015	Neuroprotective effect and underlying mechanism of sodium danshensu [3-(3,4-dihydroxyphenyl) lactic acid from Radix and Rhizoma Salviae miltiorrhizae = Danshen] against cerebral ischemia and reperfusion injury in rats.
1/2015	Effects and Mechanism of Combination of Rhein and Danshensu in the Treatment of Chronic Kidney Disease.
1/2013	Cardioprotective effect of Danshensu against myocardial ischemia/reperfusion injury and inhibits apoptosis of H9c2 cardiomyocytes via Akt and ERK1/2 phosphorylation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chao Guo Research Topics

Disease

37	Neoplasms (Cancer) 01/2022 - 06/2005
17	Reperfusion Injury 07/2022 - 12/2012
17	Infarction (Infarctions) 01/2022 - 12/2012
12	Inflammation (Inflammations) 01/2022 - 11/2013
11	Brain Ischemia (Cerebral Ischemia) 07/2022 - 12/2012
9	Neoplasm Metastasis (Metastasis) 12/2019 - 01/2012
9	Ischemia 11/2017 - 12/2012
8	Myocardial Ischemia (Ischemic Heart Diseases) 11/2017 - 01/2013
6	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 07/2022 - 12/2012
6	Ischemic Stroke 07/2022 - 02/2019
6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 10/2016
6	Stroke (Strokes) 08/2019 - 09/2014
5	Myocardial Infarction 05/2022 - 04/2017
5	Pain (Aches) 01/2022 - 03/2014
4	Hearing Loss (Hearing Impairment) 06/2022 - 01/2017
4	Carcinoma (Carcinomatosis) 12/2021 - 01/2014
4	Wounds and Injuries (Trauma) 01/2021 - 12/2015
4	Carcinogenesis 01/2021 - 01/2015
4	Lung Neoplasms (Lung Cancer) 12/2020 - 06/2005
4	Renal Cell Carcinoma (Grawitz Tumor) 11/2018 - 09/2010
3	Brain Injuries (Brain Injury) 07/2022 - 11/2014
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 01/2020
3	Hypertension (High Blood Pressure) 11/2021 - 01/2020
3	Thymoma (Thymic Carcinoma) 09/2021 - 09/2020
3	Cholangiocarcinoma 05/2021 - 07/2019
3	Neurologic Manifestations (Neurological Manifestations) 01/2021 - 12/2012
3	Insulin Resistance 01/2020 - 07/2015
3	Brain Edema (Cerebral Edema) 01/2020 - 11/2018
3	Fibrosis (Cirrhosis) 06/2019 - 06/2013
3	Cardiovascular Diseases (Cardiovascular Disease) 09/2017 - 01/2013
3	Diabetic Cardiomyopathies 01/2017 - 01/2015
3	Hyperglycemia 01/2017 - 01/2015
3	Osteosarcoma (Osteogenic Sarcoma) 08/2016 - 01/2015
2	Shock 05/2022 - 07/2012
2	Neuralgia (Stump Neuralgia) 01/2022 - 06/2002
2	Leukemia 01/2022 - 01/2021
2	Infections 12/2021 - 01/2021
2	Colorectal Neoplasms (Colorectal Cancer) 12/2021 - 09/2019
2	Cerebral Hemorrhage 11/2021 - 01/2020
2	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 10/2019
2	Apnea 01/2021 - 07/2020
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2021 - 01/2021
2	Body Weight (Weight, Body) 01/2021 - 05/2013
2	Delirium 01/2021 - 01/2018

Drug/Important Bio-Agent (IBA)

18	Proteins (Proteins, Gene)FDA Link 06/2022 - 06/2005
9	Neuroprotective AgentsIBA 07/2022 - 12/2012
9	AntioxidantsIBA 11/2020 - 02/2013
8	Pharmaceutical PreparationsIBA 01/2022 - 03/2014
7	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2015
6	Oxygen (Dioxygen)IBA 07/2022 - 02/2013
6	CytokinesIBA 12/2021 - 11/2013
6	Long Noncoding RNAIBA 05/2021 - 09/2017
5	Glucose (Dextrose)FDA LinkGeneric 07/2022 - 02/2013
5	RNA (Ribonucleic Acid)IBA 06/2022 - 09/2010
5	Interleukin-6 (Interleukin 6)IBA 01/2022 - 11/2013
5	Biological ProductsIBA 01/2022 - 09/2019
5	Messenger RNA (mRNA)IBA 12/2021 - 06/2005
5	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020 - 01/2015
5	3,4-dihydroxyphenyllactic acidIBA 12/2017 - 01/2013
4	EnzymesIBA 12/2021 - 11/2013
4	Angiotensin IIIBA 11/2021 - 01/2020
4	Ascorbic Acid (Vitamin C)FDA LinkGeneric 01/2021 - 11/2019
4	Blood Glucose (Blood Sugar)IBA 01/2021 - 05/2013
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 04/2017
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020 - 01/2015
4	Formaldehyde (Formol)FDA Link 04/2017 - 09/2010
4	FlavonoidsIBA 01/2017 - 03/2015
3	Sirtuin 1IBA 01/2022 - 12/2015
3	Hemoglobins (Hemoglobin)IBA 11/2021 - 01/2020
3	Phosphotransferases (Kinase)IBA 01/2021 - 08/2015
3	7,3'-dihydroxy-4'-methoxyisoflavoneIBA 01/2021 - 12/2012
3	Capsules (Microcapsules)IBA 01/2021 - 01/2019
3	Mitogen-Activated Protein Kinase 1 (p42 MAP Kinase)IBA 01/2021 - 05/2020
3	MicroRNAs (MicroRNA)IBA 12/2020 - 09/2010
3	chikusetsu saponin IVaIBA 01/2020 - 12/2015
3	ParaffinIBA 12/2019 - 09/2010
3	puerarinIBA 09/2019 - 06/2013
3	BerberineIBA 08/2019 - 12/2016
3	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 02/2018 - 11/2017
3	SaponinsIBA 02/2018 - 12/2015
3	VaccinesIBA 02/2018 - 03/2015
3	hydroxysafflor yellow AIBA 12/2017 - 09/2014
3	LipopolysaccharidesIBA 09/2016 - 03/2013
3	lithospermate BIBA 03/2015 - 02/2013
2	AcidsIBA 07/2022 - 11/2014
2	Heme Oxygenase-1IBA 07/2022 - 11/2014
2	Mitogen-Activated Protein Kinase 14IBA 01/2022 - 01/2021
2	CalciumIBA 01/2022 - 01/2021
2	IronIBA 12/2021 - 11/2021
2	Therapeutic UsesIBA 09/2021 - 03/2015
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 10/2019
2	Triglycerides (Triacylglycerol)IBA 01/2021 - 07/2015
2	NF-kappa B (NF-kB)IBA 01/2021 - 03/2015
2	mitoquinoneIBA 11/2020 - 01/2020

Therapy/Procedure

12	Therapeutics 02/2022 - 01/2013
4	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2022 - 03/2014
3	Activities of Daily Living (ADL) 10/2022 - 01/2020
3	Immunotherapy 01/2022 - 01/2018
3	Drug Therapy (Chemotherapy) 08/2017 - 01/2015
2	Percutaneous Coronary Intervention 05/2022 - 01/2021